With nine drugs expected to lose their patents between 2011 and 2016, the US Cholesterol Lowering Agents (Dyslipidemia) Market currently stands at the edge of a major patent cliff. IMARC Group, one of the world’s leading research and advisory firms, expects in its new report” US Cholesterol Lowering Agents Market Report & Forecast: On the Edge of a Patent Cliff” that despite a strong performance of Crestor (Rosuvatation), the avalanche of patent expiries and a thin drug pipeline will erode this market of sales worth more than US$ 8.7 billion in the next six years.
This report provides an analytical and statistical insight into the US Cholesterol Lowering agents Market. The study that has been undertaken using both desk-based as well as qualitative primary research has analyzed the following aspects of this market:
Key Aspects Analyzed:
Understanding the Epidemiology of Dyslipidemia in the US:
Focus of the Analysis:
- Current and future size of the dyslipidemia patient pool
- Current and future prevalence of dyslipidemia
- Current and future diagnosis rates for dyslipidemia
- Current and future drug treatment rates for dyslipidemia
Comprehensive Evaluation of the US Cholesterol Lowering Agents Market:
Classes Covered: Statins, Fixed Dose Combinations, Ion Exchange Resins, Fibrates, Other Cholesterol Triglyceride Regulators, Omega-3 Acid Ethyl Esters and CETP Inhibitors
Molecules Covered: Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin, Fluvastatin, Lovastatin, Pitavastatin, Ezetimibe/Simvastatin, ER Niacin/Simvastatin, Atorvastatin/Amlodipine, ER Naicin/Laropiprant, Ezetimibe/Atorvastatin, ER Niacin/Laropiprant/Simvastatin, Colesevelam, Cholestyramine, Colestipol, Fenofibrate, Fenofibric Acid, Gemfibrozil, Dalcetrapib, Anacetrapib
Focus of the Analysis for Each Class & Molecule:
- Drug Overview
- Historical Sales
- Key Players and Brands in the Market
- Patent Expiries and Generic Launch
- Sales Forecast
Comprehensive Evaluation of Generic Opportunities in the US Cholesterol Lowering Agents Market:
- Historical Patent Expiries and the Evolution of Generic Drugs
- Historical Value and Volume share of Brands and Generics
- Future Patent Expiries and Generic Launches
- Value and Volume Forecasts for Brands and Generics
Information Sources:
Information has been sourced from both primary and secondary sources:
- Primary sources include industry surveys and face to face/telephone interviews with industry experts.
- Secondary sources include proprietary databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, industry portals, government sources and access to more than 4000 paid databases.